Ebb & Flow

Ambrx's $52 million series C round saw a variety of investors jump into the private company, including pension funds and hedges. The company maintains it was able to attract the unusual suspects because its site-directed pegylation platform can encompass the protein drug space, with the prospect for near-term revenues as well.

The round was led by Apposite Capital. Other new investors included the Dow Employees' Pension Plan and Union Carbide Employees' Pension Plan, as well as Glynn Ventures...